Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.17.23: angiotensin-converting enzyme 2

This is an abbreviated version!
For detailed information about angiotensin-converting enzyme 2, go to the full flat file.

Word Map on EC 3.4.17.23

Reaction

angiotensin II
+
H2O
=
angiotensin-(1-7)
 +
L-phenylalanine

Synonyms

ACE, ACE 2, ACE-2, ACE-related carboxypeptidase, ACE2, ACE2 homologue, ACEH, ACEII, Ang converting enzyme 2, angiotensin converting enzyme 2, angiotensin converting enzyme II, angiotensin converting enzyme-2, angiotensin II converting enzyme 2, angiotensin-converting enzyme, angiotensin-converting enzyme 2, angiotensin-converting enzyme homolog, angiotensin-converting enzyme homologue, angiotensin-converting enzyme type 2, angiotensin-converting enzyme-2, angiotensin-converting enzyme-like protein, angiotensin-converting enzyme-related carboxypeptidase, angiotensinase, hACE2, sACE2, soluble angiotensin converting enzyme 2, TMPRSS2

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.17 Metallocarboxypeptidases
                3.4.17.23 angiotensin-converting enzyme 2

Inhibitors

Inhibitors on EC 3.4.17.23 - angiotensin-converting enzyme 2

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2S)-3-(biphenyl-4-yl)-2-((3S)-2-mercapto-3-methylpentanamido)propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[(2-methyl-2-sulfanylpropanoyl)amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[(2-sulfanylpropanoyl)amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[(sulfanylacetyl)amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[[(2R)-2-sulfanylbutanoyl]amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[[(2R)-3-methyl-2-sulfanylbutanoyl]amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[[(2R)-3-phenyl-2-sulfanylpropanoyl]amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[[(2S)-2-phenyl-2-sulfanylacetyl]amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[[(2S)-2-sulfanylhexanoyl]amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[[cyclobutyl(sulfanyl)acetyl]amino]propanoic acid
-
(S)-3-(biphenyl-4-yl)-2-((2R,3R)-2-mercapto-3-methylpentanamido)propanoic acid
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-cyclohexyl-2-mercaptoacetamido)propanoic acid
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-cyclopentyl-2-mercaptoacetamido)propanoic acid
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-3-(naphthalen-2-yl)propanamido)propanoic acid
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4,4-dimethylpentanamido)propanoic acid
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4-methylpentanamido)propanoic acid
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4-phenylbutanamido)propanoic acid
-
(S)-3-(biphenyl-4-yl)-2-((R)-3-cyclohexyl-2-mercaptopropanamido)propanoic acid
-
(S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-inidazol-4-yl]-ethylamino]-4-methylpentanoic acid
-
MLN-4760
(S,S)-2-{1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylamino}-4-methylpentanoic acid
i.e MLN-4760
1,3,8-trihydroxy-6-methylanthraquinone
-
1,3,8-trihydroxy-6-methylanthraquinone (emodin) blocks interaction between the SARS corona virus spike protein and its receptor angiotensin-converting enzyme 2, 94.12% inhibition at 0.05 mM
1,4-bis-(1-anthraquinonylamino)-anthraquinone
-
slight inhibition
1,8,dihydroxy-3-carboxyl-9,10-anthraquinone
-
1,8,dihydroxy-3-carboxyl-9,10-anthraquinone (rhein) exhibits slight inhibition
10-hydroxyusambarensine
binding energy -10.4 kcal/mol, and binding energy to SARS-CoV-2 spike protein is -9.4 kcal/mol
-
1N-08795
-
90% inhibition at 0.2 mM
1N-26923
-
93% inhibition at 0.2 mM
1N-27714
-
89% inhibition at 0.2 mM
1N-28616
-
93% inhibition at 0.2 mM
1S-90995
-
11% inhibition at 0.2 mM
1S-91206
-
75% inhibition at 0.2 mM
2-benzyl-3-(hydroxy-pyrrolidin-2-yl-phosphinoyl)-propionic acid
-
2-benzyl-3-[(1-benzyloxycarbonylamino-2-phenyl-ethyl)-hydroxy-phosphinoyl]-propionic acid
-
2-benzyl-3-[(1-benzyloxycarbonylamino-3-methyl-butyl)-hydroxy-phosphinoyl]-propionic acid
-
2-benzyl-3-[(1-benzyloxycarbonylamino-ethyl)-hydroxy-phosphinoyl]-propionic acid
-
2-methylphenyl-benzylsuccinic acid
-
2-[(2-carboxy-3-phenyl-propyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester
-
2-[(2-carboxy-4-methyl-pentyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester
-
2-[(2-carboxy-propyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester
-
3,4-dimethylphenyl-benzylsuccinic acid
-
3,5-dichloro-benzylsuccinate
-
3,5-dimethylphenyl-benzylsuccinic acid
-
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionylamino]-3-methyl-butyl]-hydroxy-phosphinoyl)-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid
-
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionylamino]-3-methyl-butyl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid
-
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid
-
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid
-
3-([1-[2-acetylamino-3-(4-hydroxy-phenyl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid
-
3-methylphenyl-benzylsuccinic acid
-
3-[(1-amino-2-phenyl-ethyl)-hydroxy-phosphinoyl]-2-benzylpropionic acid
-
3-[(1-amino-3-methyl-butyl)-hydroxy-phosphinoyl]-2-benzylpropionic acid
-
3-[(1-amino-ethyl)-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
3-[[1-(2-acetylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
3-[[1-(2-acetylamino-3-phenyl-propionyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
3-[[1-(2-acetylamino-4-methyl-pentanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid
-
3-[[1-(2-acetylamino-4-methyl-pentanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
3-[[1-(2-acetylamino-4-methyl-pentanoylamino)-2-phenylethyl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
3-[[1-(2-acetylamino-6-amino-hexanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
3-[[1-(2-acetylamino-propionyl)-pyrrolidin-2-yl]-hydroxyphosphinoyl]-2-benzyl-propionic acid
-
3S-95223
-
40% inhibition at 0.2 mM
4-acetylamino-5-[2-[(2-carboxy-3-phenyl-propyl)-hydroxyphosphinoyl]-pyrrolidin-1-yl]-5-oxo-pentanoic acid
-
4-methylphenyl-benzylsuccinic acid
-
4-nitrophenyl-benzylsuccinic acid
-
4S-14713
-
70% inhibition at 0.2 mM
4S-16659
-
76% inhibition at 0.2 mM
5,7-dihydroxyflavone
-
5,7-dihydroxyflavone (chrysin) is a weak inhibitor
5115980
-
1% inhibition at 0.2 mM
6-gingerol
inhibition of the ACE2 enzyme
7490938
-
20% inhibition at 0.2 mM
7850455
-
20% inhibition at 0.2 mM
7857351
-
27% inhibition at 0.2 mM
7870029
-
11% inhibition at 0.2 mM
Ac-GDYSHCSPLRYYPWWKCTYPDPEGGG-NH2
strong inhibition, most potent inhibitory peptide, i.e. DX600
Ac-GDYSHCSPLRYYPWWPDPEGGG-NH2
-
i.e. DX600
amentoflvaone
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
-
Amphotericin B
binding affinity -10.50 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties
andrographolide
inhibition of the ACE2 enzyme
angiotensin I
angiotensin II C-terminal analogs
-
screening of a library of angiotensin II C-terminal analogs identifies a number of tetrapeptides with increased ACE2 inhibition, and identifies residues critical to the binding of angiotensin II to the active site of ACE2
-
anthraquinone
-
slight inhibition
apigenin
inhibition of the ACE2 enzyme
arbidol
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
-
artemisnin
inhibition of the ACE2 enzyme
-
asparoside C
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
-
AY-NH2
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
-
benzyl (6aS,9aS)-10-benzyl-4-[benzyl(methyl)amino]-8-(cyclopropanecarbonyl)-6a,7,8,9,9a,10-hexahydrocyclopenta[b]pyrimido[4,5-e][1,4]diazepine-6(5H)-carboxylate
inhibits the protein-protein interaction between ACE2 and the receptor-binding domain of SARS-CoV-2 spike protein and suppresses SARS-CoV-2 infection in cultured cells by inhibiting viral entry via the modulation of ACE2. The compound does not have any adverse effect on ACE2 function
-
benzyl (6aS,9aS)-4-[benzyl(methyl)amino]-10-[(4-chlorophenyl)methyl]-8-(cyclopropanecarbonyl)-6a,7,8,9,9a,10-hexahydrocyclopenta[b]pyrimido[4,5-e][1,4]diazepine-6(5H)-carboxylate
inhibits the protein-protein interaction between ACE2 and the receptor-binding domain of SARS-CoV-2 spike protein and suppresses SARS-CoV-2 infection in cultured cells by inhibiting viral entry via the modulation of ACE2. The compound does not have any adverse effect on ACE2 function
-
benzyl (6aS,9aS)-4-[benzyl(methyl)amino]-8-(cyclopropanecarbonyl)-10-[(4-methylphenyl)methyl]-6a,7,8,9,9a,10-hexahydrocyclopenta[b]pyrimido[4,5-e][1,4]diazepine-6(5H)-carboxylate
inhibits the protein-protein interaction between ACE2 and the receptor-binding domain of SARS-CoV-2 spike protein and suppresses SARS-CoV-2 infection in cultured cells by inhibiting viral entry via the modulation of ACE2. The compound does not have any adverse effect on ACE2 function
-
benzylsuccinate
-
essentially abolishes the formation of Ang(1-9) by ACE2
Benzylsuccinic acid
-
Berberine
inhibition of the ACE2 enzyme
beta-sitosterol
inhibition of the ACE2 enzyme
bis-demethoxy curcumin
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
cepharanthine
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex
chebulagic acid
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
-
chrysin
shows a strong affinity for the active site of ACE2, ACE2-inhibitor complexes display structural stability with suitable binding energies. The interaction of chrysin with Phe40, Asp350, and Gly352 on ACE2 can interfere with the binding of SARS-CoV-2
crisimaritin
inhibition of the ACE2 enzyme
-
cryptoquindoline
binding energy -9.9 kcal/mol, and binding energy to SARS-CoV-2 spike protein is -9.5 kcal/mol
-
cryptospirolepine
binding energy -10.7 kcal/mol, and binding energy to SARS-CoV-2 spike protein is -10.6 kcal/mol
-
Cu2+
-
69% inhibition at 0.01 mM
cucurbitacin B
inhibition of the ACE2 enzyme
curcumin
inhibition of the ACE2 enzyme
cyclohexyl-benzylsuccinic acid
-
cynaropicrin
inhibition of the ACE2 enzyme
darunavir
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
denopamine
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
dicyclohexyl-benzylsuccinic acid
-
digitoxin
binding affinity -11.25 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties
dithymoquinone
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
-
DRVYIYbetaPF
-
angiotensin II chimera prepared by combining key elements of ACE2 binding and proteolytic stability, 90% inhibition at 10 microM and complete resistance to cleavage over 5 h
DRVYIYPF
-
angiotensin II chimera prepared by combining key elements of ACE2 binding and proteolytic stability, 96% inhibition at 10 microM and 18% cleavage over 5h
ergoloid
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex
-
eriodictyol
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex
Evans blue
inhibits viral replication in a Vero-E6 cell-based SARS-CoV-2 infection assay
favipiravir
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex
glycyrrhizinate
binding affinity -11.75 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties
hesperidin
inhibition of the ACE2 enzyme; inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
hispudulin
inhibition of the ACE2 enzyme
-
hydroxychloroquine
hypericin
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex
Ile-Pro-Pro
-
inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2
isocryptolepine
binding energy to SARS-CoV-2 spike protein is -9.7 kcal/mol
-
isoniazid pyruvate
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex
-
isothymol
inhibition of the ACE2 enzyme
-
ivermectin
Leu-Pro-Pro
-
inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2
lumacaftor
inhibits viral replication in a Vero-E6 cell-based SARS-CoV-2 infection assay
-
luteolin
shows a strong affinity for the active site of ACE2, ACE2-inhibitor complexes display structural stability with suitable binding energies
menthol
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex
methylene blue
binding energy -4.89 kcal/mol, KD value 0.621mM
MLN 4760
MLN-4760
MLN4760
-
-
N-acetyl-D-glucosamine
binding energy -5.6 kcal/mol
N-[(1S)-1-carboxy-3-methylbutyl]-3-(3,5-dichlorobenzyl)-L-histidine
enzyme-specific inhibitor
N-[(1S)-1-carboxy-3-methylbutyl]-3-(3,5-dichlorophenyl)-L-histidine
-
i.e. C16, a ACE2 specific inhibitor
naringin
inhibition of the ACE2 enzyme
neoandrographolide
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
Nitrofurantoin
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex
orientin
inhibition of the ACE2 enzyme
paritaprevir
inhibition of the ACE2 enzyme
phenylbenzylsuccinic acid
-
PHVF
-
angiotensin II analog, shows almost saturating levels of inhibition at the screening concentration of 100 microm
piceatannol
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
pimozide
effectively binds to the ACE2 binding site for SARS-CoV-2 spike protein, does not show stability during molecular dynamics simulation
Pro-Phe
pseudojervine
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
-
PYPF
-
angiotensin II analog, shows almost saturating levels of inhibition at the screening concentration of 100 microm
PYVF
-
angiotensin II analog, shows almost saturating levels of inhibition at the screening concentration of 100 microm
quercetin
quercetin-3-O-galatosyl-rhamnosyl-glucoside
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
-
Quinacrine
KD value 0.102 mM
Rapamycin
binding affinity -10.57 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties
raspberry ketone
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex
-
rifaximin
binding affinity -10.54 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties
-
rutin
inhibition of the ACE2 enzyme
rutin DAB10
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
-
saikosaponin A
inhibition of the ACE2 enzyme
sennoside A
binding energy -4.51 kcal/mol, KD value 0.041 mM
sodium lifitegrast
inhibits viral replication in a Vero-E6 cell-based SARS-CoV-2 infection assay
-
spinochrome A
inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex
-
strychnopentamine
binding energy -9.9 kcal/mol
-
sunitinib
KD value 0.781 mM
T0507-4963
-
41% inhibition at 0.2 mM
T0513-5544
-
4% inhibition at 0.2 mM
T0515-3007
-
13% inhibition at 0.2 mM
telmisartan
-
specific angiotensin II type 1 receptor blocker
thymoquinone
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex
Ursodeoxycholic acid
effectively binds to the ACE2 binding site for SARS-CoV-2 spike protein, does not show stability during molecular dynamics simulation
Val-Pro-Pro
-
inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2
varenicline
binding energy -4.42 kcal/mol, KD value 0.017 mM
-
vitexin
inhibition of the ACE2 enzyme
Z-prolyl-prolinal
-
-
additional information
-